Rexulti - Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. - BIO International Convention

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

Home Otsuka US

Rexulti (brexpiprazole) Drug Overview 2019 - Research and Markets

FDA approves Rexulti for agitation tied to Alzheimer's dementia, Daily therapy is first to be approved for this use in US

Home Otsuka US

Pharmaceutical Business Products

Rexulti: Package Insert

Arash Raoufinia, MS, PharmD on LinkedIn: Early Phase and Translational Medicine (Clinical Pharmacology) - Otsuka…

FDA contacts Otsuka over marketing of depression drug co-developed with Lundbeck — MedWatch

Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder

Rexulti Lawsuit - Prescription Drug Journal™